FILING ANALYSIS · FRIDAY, NOVEMBER 13
IRulya Therapeutics Inc. IRLA — 8-K: Results of Operations and Financial Condition
neutral
IRulya Therapeutics reported a net loss of $27.7 million and a cash position of $105.2 million, with expected funding through the end of 2028, but no quantified surprises in the announcement
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →